overactive bladder
Conditions
Interventions
Arm of oxybutynin tape 73.5mg per one day for 8 weeks.
Arm of mirabegron 50mg per one day for 8 weeks.
Sponsors
Department of Urology, school of medicine, Shinshu university
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 20 years of age or older of overactive bladder female patients with nocturia symptoms.
Exclusion criteria
Exclusion criteria: (1) Patients in the study drug administration proposed site with a skin disease and skin abnormalities. (2) Patients with residual urine volume greater than 100mL. (3) Patients with a difficulty in going to the bathroom without the assistance. (4) Patients with a history of hypersensitivity of Oxybutynin hydrochloride or Mirabegron. (5) Patients receiving flecainide acetate or propafenone hydrochloride. (6) Patients with severe blood, liver, kidney disease and severe arrhythmia, suffering from cardiovascular diseases such as congestive heart failure. (7) Patients with hypokalemia (less than 3.5mEq / L). (8) Patients with paralytic ileus, ulcerative colitis, stomach atony, patients suffering from gastrointestinal diseases, such as bowel atony. (9) Patients with Parkinson's syndrome, dementia, suffering from psychiatric and neurological disorders or cerebrovascular disorders such as myasthenia gravis. (10) Patients with a glaucoma. (11) Patients with a hyperthyroidism. (12) Patients with malignant tumors. (13) Pregnant patients, patients in lactating, and patients want to become pregnant during test period. (14) Patients who participated in the other interventions tested within 16 weeks prior to study drug administration. (15) Other, patient that investigators or test sharing doctor was ineligible as a subject of the present study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| N-QOL score | — |
Countries
Japan
Contacts
Public ContactToshiro Suzuki
Department of Urology, school of medicine, Shinshu university Urology
Outcome results
None listed